TY - JOUR T1 - Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 151 LP - 160 VL - 13 IS - 2 AU - XUAN CHEN AU - YUE LIU AU - JIAN WU AU - HUARONG HUANG AU - ZHIYUN DU AU - KUN ZHANG AU - DAIYING ZHOU AU - KAYLYN HUNG AU - SUSAN GOODIN AU - XI ZHENG Y1 - 2016/03/01 UR - http://cgp.iiarjournals.org/content/13/2/151.abstract N2 - Aim: To investigate the effects and mechanisms of docetaxel and atorvastatin administered individually or in combination on prostate cancer cells. Materials and Methods: Cell growth and apoptosis were determined by the trypan blue exclusion assay and morphological assessment of cells was performed with propidium iodide. NF-κB activity was determined by luciferase reporter gene assay and the western blot assay was used to determine the levels of Bcl-2, phospho-Akt, VEGF, and phospho-Erk1/2. Results: Results showed that following pre-treatment with cholesterol, resistance of PC-3 prostate cancer cells to docetaxel was increased. The combination of docetaxel with atorvastatin potently inhibited growth and induced apoptosis in PC-3 cells. Mechanistic studies indicated that induction of apoptosis in PC-3 cells was associated with significant decreases in the levels of Bcl-2, VEGF, phosphor-Akt, and phosphor-Erk1/2. Conclusion: Treatment with cholesterol decreased the sensitivity of prostate cancer cells to docetaxel. Docetaxel in combination with cholesterol-lowering drugs such as atorvastatin may be an effective strategy for inhibiting the growth of prostate cancer. ER -